Seven ADR reports of gangrene and/or peripheral cyanosis associated with the use of norepinephrine [noradrenaline; Cardiamed]

Excerpt

Seven ADR reports of gangrene and/or peripheral cyanosis associated with the use of norepinephrine [noradrenaline; Cardiamed] have been received by the Malaysian National Pharmaceutical Control Bureau. The patients developed gangrene on their toes, fingers and legs and/or peripheral cyanosis 2 to 5 days after the injection. All patients received the recommended norepinephrine dose of 0.13 to 0.3 µg/kg/min diluted in 5% dextrose saline, infused through a dedicated central line. Following discussions, the manufacturer of Cardiamed voluntarily recalled Cardiamed batches from the market due to potential patient safety concerns. …